Patents by Inventor Vladimir Jankovic
Vladimir Jankovic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230323470Abstract: The present disclosure provides methods for treating or inhibiting the growth of a tumor, including selecting a patient with cancer, wherein the patient has a tumor with threshold levels of both tumor mutation burden and expression of major histocompatibility complex, and administering to the patient a therapeutically effective amount of programmed death 1 (PD-1) inhibitor (e.g., an anti-PD-1 antibody or antigen-binding fragment thereof). In some embodiments, the cancer is skin cancer, such as basal cell carcinoma or cutaneous squamous cell carcinoma.Type: ApplicationFiled: August 25, 2021Publication date: October 12, 2023Inventors: Matthew G. Fury, Gavin Thurston, Vladimir Jankovic, Nathalie M. Fiaschi, Israel Lowy
-
Publication number: 20220241347Abstract: Provided herein are compositions of placenta-derived adherent cell exosomes and methods of making and using the same. In one aspect, provided herein are compositions comprising exosomes produced by and/or derived from placental cells, e.g., placenta-derived adherent cells. In certain embodiments, the exosomes provided herein are produced by placenta-derived adherent cells that have been cultured in vitro for, e.g., 1, 2, 3, 4, 5, 6 or more passages.Type: ApplicationFiled: October 7, 2021Publication date: August 4, 2022Applicant: Celularity Inc.Inventors: Eric Law, Andrew Morschauser, Aleksander Francki, Jennifer Paredes, Kathy Karasiewicz-Mendez, Allan Reduta, Vladimir Jankovic, Ivana Djuretic, Robert J. Hariri
-
Patent number: 11173182Abstract: Provided herein are compositions of placenta-derived adherent cell exosomes and methods of making and using the same. In one aspect, provided herein are compositions comprising exosomes produced by and/or derived from placental cells, e.g., placenta-derived adherent cells. In certain embodiments, the exosomes provided herein are produced by placenta-derived adherent cells that have been cultured in vitro for, e.g., 1, 2, 3, 4, 5, 6 or more passages.Type: GrantFiled: January 10, 2020Date of Patent: November 16, 2021Assignee: Celularity Inc.Inventors: Eric Law, Andrew Morschauser, Aleksander Francki, Jennifer Paredes, Kathy Karasiewicz-Mendez, Allan Reduta, Vladimir Jankovic, Ivana Djuretic, Robert J. Hariri
-
Publication number: 20210008109Abstract: Provided herein are methods of treating a hematological disorder, a solid tumor, or an infectious disease in a subject in need thereof using natural killer cells in combination with a second agent, or using natural killer cells with genetic modifications for target specificity and/or homing specificity.Type: ApplicationFiled: February 18, 2020Publication date: January 14, 2021Applicant: CELGENE CORPORATIONInventors: Lin KANG, Xiaokui ZHANG, Jeffrey HARRIS, Vladimir JANKOVIC
-
Publication number: 20180346877Abstract: Provided herein are methods of producing natural killer (NK) cells and/or ILC3 cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.Type: ApplicationFiled: October 14, 2016Publication date: December 6, 2018Applicant: CELULARITY, INC.Inventors: Xiaokui ZHANG, Ivana DJURETIC, Lin KANG, Vanessa VOSKINARIAN-BERSE, Bhavani STOUT, Robert J. HARIRI, Wolfgang HOFGARTNER, James EDINGER, Eric LAW, Vladimir JANKOVIC
-
Publication number: 20180071343Abstract: Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells.Type: ApplicationFiled: November 16, 2017Publication date: March 15, 2018Applicant: Celularity, Inc.Inventors: Stewart Abbot, James Edinger, Aleksander Francki, Robert J. Hariri, Vladimir Jankovic, Aleksandr Kaplunovsky, Kristen Labazzo, Eric Law, Neerav Padliya, Jennifer Paredes, Jia-Lun Wang
-
Publication number: 20180021378Abstract: Provided herein are methods of treating a hematological disorder, a solid tumor, or an infectious disease in a subject in need thereof using natural killer cells in combination with a second agent, or using natural killer cells with genetic modifications for target specificity and/or homing specificity.Type: ApplicationFiled: December 30, 2015Publication date: January 25, 2018Applicant: ANTHROGENESIS CORPORATIONInventors: Lin KANG, Xiaokui ZHANG, Jeffrey HARRIS, Vladimir JANKOVIC
-
Publication number: 20170290861Abstract: Provided herein are methods of using tissue culture plastic-adherent placental cells, e.g. placental stem cells, in the treatment of diabetic foot ulcer (DFU).Type: ApplicationFiled: September 25, 2015Publication date: October 12, 2017Applicant: Anthrogenesis CorporationInventors: Steven A. FISCHKOFF, Denesh CHITKARA, Uri HERZBERG, Vladimir JANKOVIC
-
Publication number: 20170252379Abstract: Provided herein are compositions of placenta-derived adherent cell exosomes and methods of making and using the same. In one aspect, provided herein are compositions comprising exosomes produced by and/or derived from placental cells, e.g., placenta-derived adherent cells. In certain embodiments, the exosomes provided herein are produced by placenta-derived adherent cells that have been cultured in vitro for, e.g., 1, 2, 3, 4, 5, 6 or more passages.Type: ApplicationFiled: October 8, 2015Publication date: September 7, 2017Applicant: Anthrogenesis CorporationInventors: Eric LAW, Andrew MORSCHAUSER, Aleksandar FRANCKI, Jennifer PAREDES, Kathy E. KARASIEWICZ-MENDEZ, Allan REDUTA, Vladimir JANKOVIC, Ivana DJURETIC
-
Publication number: 20160361366Abstract: Provided herein are novel angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising, such cells. Further provided herein are methods of obtaining such cells and methods of using the cells in the treatment of individuals.Type: ApplicationFiled: October 22, 2015Publication date: December 15, 2016Applicant: ANTHROGENESIS CORPORATIONInventors: Stewart Abbot, James W. Edinger, Aleksandar Francki, Aleksandr Kaplunovsky, Vladimir Jankovic, Kristen Labazzo, Eric Law, Neerav Padliya, Jennifer Paredes, Jia-Lun Wang
-
Publication number: 20160106784Abstract: Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells.Type: ApplicationFiled: December 22, 2015Publication date: April 21, 2016Applicant: ANTHROGENESIS CORPORATIONInventors: Stewart Abbot, James W. Edinger, Aleksandar Francki, Robert J. Hariri, Vladimir Jankovic, Aleksandr Kaplunovsky, Kristen Labazzo, Eric Law, Neerav D. Padliya, Jennifer Paredes, Jia-Lun Wang
-
Patent number: 9254302Abstract: Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells.Type: GrantFiled: April 6, 2011Date of Patent: February 9, 2016Assignee: ANTHROGENESIS CORPORATIONInventors: Stewart Abbot, James W. Edinger, Aleksandar Francki, Robert J. Hariri, Vladimir Jankovic, Aleksandr Kaplunovsky, Kristen Labazzo, Eric Law, Neerav D. Padliya, Jennifer Paredes, Jia-Lun Wang
-
Patent number: 9198938Abstract: Provided herein are novel angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising, such cells. Further provided herein are methods of obtaining such cells and methods of using the cells in the treatment of individuals.Type: GrantFiled: December 26, 2012Date of Patent: December 1, 2015Assignee: ANTRHOGENESIS CORPORATIONInventors: Stewart Abbot, James W. Edinger, Aleksandar Francki, Aleksandr Kaplunovsky, Vladimir Jankovic, Kristen Labazzo, Eric Law, Neerav Padliya, Jennifer Paredes, Jia-Lun Wang
-
Publication number: 20150225697Abstract: Provided herein are methods of producing natural killer (NK) cells and NK progenitor cell populations using a two-step expansion and differentiation method. Also provided herein are methods of producing populations of NK cells and NK progenitor cell populations using a three-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells, the NK cell populations, and the NK progenitor cell populations produced by the methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells, the NK cell populations, and the NK progenitor cell populations produced by the methods described herein to an individual having the cancer or viral infection.Type: ApplicationFiled: August 13, 2013Publication date: August 13, 2015Applicant: Anthrogenesis CorporationInventors: Eric Law, Lin Kang, Vladimir Jankovic, Xiaokui Zhang, Stewart Abbot, Robert J. Hariri
-
Publication number: 20150023926Abstract: Provided herein are methods of treating individuals having suffered exposure to radiation, e.g., individuals having radiation injury, by administering to the individuals angiogenic cells from amnion, referred to as amnion derived adherent cells, or populations of and compositions comprising, such cells.Type: ApplicationFiled: July 13, 2012Publication date: January 22, 2015Applicant: ANTHROGENESIS CORPORATIONInventors: Aleksandar Francki, Ajai Pal, Robert J. Hariri, Vladimir Jankovic
-
Publication number: 20140219970Abstract: Provided herein are compositions and methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein. Also provided herein are kits comprising said cells or a composition thereof.Type: ApplicationFiled: September 16, 2013Publication date: August 7, 2014Applicant: Anthrogenesis CorporationInventors: James W. Edinger, Steven Alan Fischkoff, Aleksandar Francki, Vladimir Jankovic, Bitao Liang, Philippe Martin, Cynthia Ray, Xiaockui Zhang
-
Publication number: 20140072538Abstract: Provided herein are methods of treating individuals having suffered exposure to radiation, e.g., individuals having radiation injury, by administering to the individuals angiogenic cells from amnion, referred to as amnion derived adherent cells, or populations of, and compositions comprising, such cells.Type: ApplicationFiled: July 12, 2013Publication date: March 13, 2014Inventors: Aleksandar Francki, Ajai Pal, Robert J. Hariri, Vladimir Jankovic
-
Patent number: 8562973Abstract: Methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder using placental cells are described. Also describe are kits comprising placental stem cells or a composition thereof that can be used in methods of treating sarcoidosis or a sarcoidosis-related disease or disorder.Type: GrantFiled: April 6, 2011Date of Patent: October 22, 2013Assignee: Anthrogenesis CorporationInventors: James W. Edinger, Steven Alan Fischkoff, Aleksandar Francki, Vladimir Jankovic, Bitao Liang, Philippe Martin, Cynthia Ray, Xiaokui Zhang
-
Patent number: 8367409Abstract: Provided herein are novel angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising, such cells. Further provided herein are methods of obtaining such cells and methods of using the cells in the treatment of individuals.Type: GrantFiled: November 19, 2009Date of Patent: February 5, 2013Assignee: Anthrogenesis CorporationInventors: Stewart Abbot, James W. Edinger, Aleksandar Francki, Aleksandr Kaplunovsky, Vladimir Jankovic, Kristen Labazzo, Eric Law, Neerav D. Padliya, Jennifer Paredes, Jia-Lun Wang
-
Publication number: 20120201787Abstract: Provided herein are methods of treating spinal cord and traumatic brain injuries using cells from amnion, and populations of such cells, referred to herein as “amnion derived adherent cells” (“AMDACs”).Type: ApplicationFiled: December 15, 2011Publication date: August 9, 2012Inventors: Stewart Abbot, James W. Edinger, Aleksandar Francki, Vladimir Jankovic, Aleksandr Kaplunovsky, Kristen Labazzo, Eric Law, Bitao Liang